Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

Leukemia

Volumn 24, Issue 6, 2010, Pages 1128-1138

  Tefferi, A ^a  

^a MAYO CLINIC   (United States)

Author keywords

isocitrate dehydrogenase; myelofibrosis; pathogenesis; polycythemia; thrombocythemia

Indexed keywords

BCR ABL PROTEIN; CBL PROTEIN; IKAROS TRANSCRIPTION FACTOR; ISOCITRATE DEHYDROGENASE; JANUS KINASE; JANUS KINASE 2; ONCOPROTEIN; STAT PROTEIN; ASXL1 PROTEIN, HUMAN; CBL PROTEIN, HUMAN; DNA BINDING PROTEIN; IDH1 PROTEIN, HUMAN; IKZF1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; MPL PROTEIN, HUMAN; REPRESSOR PROTEIN; TET2 PROTEIN, HUMAN; THROMBOPOIETIN RECEPTOR; TUMOR MARKER; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADDITIONAL SEX COMB LIKE 1 GENE; CASITAS B LINEAGE LYMPHOMA PROTOONCOGENE; CELL DIFFERENTIATION; CLONE; EPIGENETICS; EXON; FAMILY ZINC FINGER 1 GENE; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENETIC TRANSFORMATION; HEMATOPOIETIC STEM CELL; HUMAN; INCIDENCE; INTRACELLULAR SIGNALING; JAK2V617F GENE; MASTOCYTOSIS; MUTATION RATE; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; MYELOMONOCYTIC LEUKEMIA; MYELOPOIESIS; MYELOPROLIFERATIVE LEUKEMIA VIRUS GENE; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; ONCOGENE; PHENOTYPE; POLYCYTHEMIA; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; TET ONCOGENE FAMILY MEMBER 2 GENE; THROMBOCYTHEMIA; GENETICS; METABOLISM; MUTATION; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; PROGNOSIS;

DNA-BINDING PROTEINS; HUMANS; IKAROS TRANSCRIPTION FACTOR; ISOCITRATE DEHYDROGENASE; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; NEOPLASM PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTORS, THROMBOPOIETIN; REPRESSOR PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954581139     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.69     Document Type: Review

References (171)

1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
2. Tefferi A. The history of myeloproliferative disorders: before and after Dameshek. Leukemia 2008; 22: 3-13.
3. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
4. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 1976; 295: 913-916.
5. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981; 58: 916-919. (Pubitemid 12227928)
6. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978; 51: 189-194. (Pubitemid 8284647)
7. Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Bjorkholm M. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden. Blood 2008; 112: 2199-2204.
8. Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 2008; 111: 2785-2789.
9. Olcaydu D, Skoda RC, Looser R, Li S, Cazzola M, Pietra D et al. The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia 2009; 23: 1924-1926.
10. Olcaydu D, Harutyunyan A, Jager R, Berg T, Gisslinger B, Pabinger I et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009; 41: 450-454.
11. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009; 41: 446-449.
12. Patnaik MM, Lasho TL, Finke CM, Gangat N, Caramazza D, Siragusa S et al. MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms. Leukemia 2010, (e-pub ahead of print).
13. Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 2010; 24: 105-109.
14. Pardanani A, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Hanson CA et al. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia 2010; 24: 110-114.
15. Lambert JR, Everington T, Linch DC, Gale RE. In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Blood 2009; 114: 3018-3023.
16. Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010; 115: 2003-2007 blood-2009-2009-245381.
17. Schaub FX, Jager R, Looser R, Hao-Shen H, Hermouet S, Girodon F et al. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood 2009; 113: 2022-2027.
18. Beer PA, Delhommeau F, Lecouedic JP, Dawson MA, Chen E, Bareford D et al. Two routes to leukemic transformation following a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2009, (e-pub ahead of print).
19. James C, Mazurier F, Dupont S, Chaligne R, Lamrissi-Garcia I, Tulliez M et al. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood 2008; 112: 2429-2438.
20. Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006; 108: 1377-1380. (Pubitemid 44232040)
21. Beer PA, Jones AV, Bench AJ, Goday-Fernandez A, Boyd EM, Vaghela KJ et al. Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. Br J Haematol 2009; 144: 904-908.
22. Haeno H, Levine RL, Gilliland DG, Michor F. A progenitor cell origin of myeloid malignancies. Proc Natl Acad Sci USA 2009; 106: 16616-16621.
23. Pardanani A, Lasho TL, Finke C, Mesa RA, Hogan WJ, Ketterling RP et al. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells 2007; 25: 2358-2362. (Pubitemid 47480495)
24. Pardanani A, Lasho TL, Finke C, Markovic SN, Tefferi A. Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes. Leukemia 2007; 21: 2206-2207. (Pubitemid 47430454)
25. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301.
26. Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adelaide J, Rey J et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009; 23: 2183-2186.
27. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148. (Pubitemid 40663494)
28. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790. (Pubitemid 40570926)
29. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397. (Pubitemid 40544655)
30. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061. (Pubitemid 40386783)
31. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459-468. (Pubitemid 46193073)
32. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.
33. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472-3476.
34. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009; 113: 6182-6192.
35. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010; 362: 369-370.
36. Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010; 70: 447-452.
37. Pardanani A, Lasho T, Finke C, Mai M, McClure R, Tefferi A. IDH1 and IDH2 mutation analysis in chronic and blast phase myeloproliferative neoplasms. Leukemia 2010; in press.
38. Kurdi M, Booz GW. JAK redux: a second look at the regulation and role of JAKs in the heart. Am J Physiol Heart Circ Physiol 2009; 297: H1545-H1556.
39. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228: 273-287.
40. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007; 178: 2623-2629. (Pubitemid 46333135)
41. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008; 22: 23-30.
42. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009; 23: 1441-1445.
43. Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007; 21: 1658-1668. (Pubitemid 47086756)
44. Lasho TL, Tefferi A, Hood JD, Verstovsek S, Gilliland DG, Pardanani A. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon mutations as well as mutation negative patients. Leukemia 2008; 22: 1790-1792.
45. Tefferi A. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. J Cell Mol Med 2009; 13: 215-237.
46. Renneville A, Quesnel B, Charpentier A, Terriou L, Crinquette A, Lai JL et al. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia 2006; 20: 2067-2070.
47. Schmitt-Graeff AH, Teo SS, Olschewski M, Schaub F, Haxelmans S, Kirn A et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2008; 93: 34-40. (Pubitemid 351156149)
48. Atallah E, Nussenzveig R, Yin CC, Bueso-Ramos C, Tam C, Manshouri T et al. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. Leukemia 2008; 22: 1295-1298. (Pubitemid 351833812)
49. Steensma DP, McClure RF, Karp JE, Tefferi A, Lasho TL, Powell HL et al. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 2006; 20: 971-978. (Pubitemid 43797287)
50. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferative disorders and myelodysplastic syndromes. Blood 2005; 106: 1207-1209. (Pubitemid 41129580)
51. Inami M, Yamaguchi H, Hasegawa S, Mitamura Y, Kosaka F, Kobayashi A et al. Analysis of the exon 12 and 14 mutations of the JAK2 gene in Philadelphia chromosome-positive leukemia. Leukemia 2008; 22: 216.
52. Hussein K, Bock O, Theophile K, Seegers A, Arps H, Basten O et al. Chronic myeloproliferative diseases with concurrent BCRABL junction and JAK2V617F mutation. Leukemia 2008; 22: 1059-1062. (Pubitemid 351689890)
53. Patel RK, Lea NC, Heneghan MA, Westwood NB, Milojkovic D, Thanigaikumar M et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006; 130: 2031-2038. (Pubitemid 43816970)
54. Bellanne-Chantelot C, Jego P, Lionne-Huyghe P, Tulliez M, Najman A. The JAK2(V617F) mutation may be present several years before the occurrence of overt myeloproliferative disorders. Leukemia 2008; 22: 450-451. (Pubitemid 351250559)
55. Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D et al. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol 2005; 131: 166-171. (Pubitemid 43899681)
56. Melzner I, Weniger MA, Menz CK, Moller P. Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Leukemia 2006; 20: 157-158.
57. Passamonti F, Rumi E, Pietra D, Lazzarino M, Cazzola M. JAK2 (V617F) mutation in healthy individuals. Br J Haematol 2007; 136: 678-679. (Pubitemid 46148209)
58. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106: 3377-3379. (Pubitemid 41609169)
59. Kilpivaara O, Levine RL. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia 2008; 22: 1813-1817.
60. Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA 2005; 102: 18962-18967. (Pubitemid 43049549)
61. Funakoshi-Tago M, Tago K, Abe M, Sonoda Y, Kasahara T. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant. J Biol Chem 2010; 285: 5296-5307.
62. Dawson MA, Bannister AJ, Gottgens B, Foster SD, Bartke T, Green AR et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009; 461: 819-822.
63. Kota J, Caceres N, Constantinescu SN. Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia 2008; 22: 1828-1840.
64. Li WX. Canonical and non-canonical JAK-STAT signaling. Trends Cell Biol 2008; 18: 545-551.
65. Cleyrat C, Jelinek J, Girodon F, Boissinot M, Ponge T, Harousseau JL et al. JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5. Leukemia 2010, (e-pub ahead of print).
66. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010, (e-pub ahead of print).
67. Wang YL, Vandris K, Jones A, Cross NC, Christos P, Adriano F et al. JAK2 mutations are present in all cases of polycythemia vera. Leukemia 2008; 22: 1289. (Pubitemid 351833808)
68. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007; 21: 1960-1963. (Pubitemid 47299970)
69. Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008; 111: 1686-1689. (Pubitemid 351213460)
70. Patnaik MM, Tefferi A. The complete evaluation of erythrocytosis: congenital and acquired. Leukemia 2009; 23: 834-844.
71. da Costa Reis Monte-Mor B, Plo I, da Cunha AF, Costa GG, de Albuquerque DM, Jedidi A et al. Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage. Leukemia 2009; 23: 144-152.
72. Plo I, Nakatake M, Malivert L, de Villartay JP, Giraudier S, Villeval JL et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008; 112: 1402-1412.
73. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008; 111: 3931-3940.
74. Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, Takenaka K et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia 2008; 22: 87-95.
75. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008; 22: 1299-1307.
76. Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E et al. Leukemic blasts in transformed JAK2-V617Fpositive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007; 110: 375-379. (Pubitemid 47026857)
77. Jamal R, Belisle C, Lessard MC, Hebert J, Roy DC, Levine R et al. Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation. Leukemia 2008; 22: 1472-1474. (Pubitemid 352006101)
78. Kralovics R. Genetic complexity of myeloproliferative neoplasms. Leukemia 2008; 22: 1841-1848.
79. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007; 21: 1952-1959. (Pubitemid 47299969)
80. Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, Antonioli E et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007; 110: 4030-4036. (Pubitemid 350248459)
81. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY et al. The JAK2 tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 2005; 131: 320-328. (Pubitemid 43899664)
82. Tefferi A, Strand JJ, Lasho TL, Knudson RA, Finke CM, Gangat N et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 2007; 21: 2074-2075. (Pubitemid 47299994)
83. Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007; 109: 2279-2284. (Pubitemid 46801558)
84. Campbell PJ, Griesshammer M, Dohner K, Dohner H, Kusec R, Hasselbalch HC et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006; 107: 2098-2100. (Pubitemid 43289395)
85. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945-1953. (Pubitemid 41713984)
86. Palandri F, Ottaviani E, Salmi F, Catani L, Polverelli N, Fiacchini M et al. JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients. Leuk Lymphoma 2009; 50: 247-253.
87. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895-2901.
88. Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009; 114: 1477-1483.
89. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008; 22: 756-761. (Pubitemid 351559282)
90. Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L et al. Relationship between granulocyte JAK2 (V617F) mutant allele burden and risk of progression to myelofibrosis in polycythemia vera: a prospective study of 338 patients. ASH Annual Meeting Abstracts 2009; 114: 751.
91. Tefferi A, Lasho TL, Gilliland G. JAK2 mutations in myeloproliferative disorders. N Engl J Med 2005; 353: 1416-1417;author reply 1416-1417.
92. Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006; 106: 631-635. (Pubitemid 43157627)
93. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R et al. Clinical profile of homozygous JAK2 617V4F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007; 110: 840-846. (Pubitemid 47267419)
94. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010; 115: 778-782, blood-2009-2008-238956.
95. Politou M, Zoi C, Dahabreh IJ, Rallidis L, Gialeraki A, Loukopoulos D et al. No evidence of frequent association of the JAK2 V617F mutation with acute myocardial infarction in young patients. Leukemia 2009; 23: 1008-1009.
96. Butcher CM, Hahn U, To LB, Gecz J, Wilkins EJ, Scott HS et al. Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients. Leukemia 2008; 22: 870-873. (Pubitemid 351552644)
97. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097. (Pubitemid 47281402)
98. Passamonti F, Schnittger S, Girodon F, Kiladjian J-J, McMullin MF, Ruggeri M et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations: a European Multicenter Study. ASH Annual Meeting Abstracts 2009; 114: 3904.
99. Martinez-Aviles L, Besses C, Alvarez-Larran A, Cervantes F, Hernandez-Boluda JC, Bellosillo B. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis. Haematologica 2007; 92: 1717-1718. (Pubitemid 350248259)
100. Teofili L, Giona F, Torti L, Cenci T, Ricerca BM, Rumi C et al. Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica 2010; 95: 65-70.
101. Moliterno AR, Williams DM, Gutierrez-Alamillo LI, Salvatori R, Ingersoll RG, Spivak JL. Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci USA 2004; 101: 11444-11447. (Pubitemid 39038366)
102. Hussein K, Bock O, Theophile K, Schulz-Bischof K, Porwit A, Schlue J et al. MPLW515L mutation in acute megakaryoblastic leukaemia. Leukemia 2009; 23: 852-855.
103. Schnittger S, Haferlach C, Beelen DW, Bojko P, Dengler R, Diestelrath A et al. Detection of three different MPLW515 mutations in 10.1% of all JAK2 V617 unmutated ET and 9.3% of all JAK2 V617F unmutated OMF: a study of 387 patients. ASH Annual Meeting Abstracts 2007; 110: 2546.
104. Vannucchi AM, Antonioli E, Pancrazzi A, Guglielmelli P, Di Lollo S, Alterini R et al. The clinical phenotype of patients with essential thrombocythemia harboring MPL 515W4L/K mutation. ASH Annual Meeting Abstracts 2007; 110: 678.
105. Guglielmelli P, Pancrazzi A, Bergamaschi G, Rosti V, Villani L, Antonioli E et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 2007; 137: 244-247. (Pubitemid 46537640)
106. Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008; 112: 141-149.
107. Chaligne R, James C, Tonetti C, Besancenot R, Le Couedic JP, Fava F et al. Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood 2007; 110: 3735-3743. (Pubitemid 350159644)
108. Chaligne R, Tonetti C, Besancenot R, Roy L, Marty C, Mossuz P et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia 2008; 22: 1557-1566.
109. Pecquet C, Staerk J, Chaligne R, Goss V, Lee KA, Zhang X et al. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood 2010; 115: 1037-1048.
110. Lasho TL, Pardanani A, McClure RF, Mesa RA, Levine RL, Gary Gilliland D et al. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol 2006; 135: 683-687. (Pubitemid 44674079)
111. Szpurka H, Gondek LP, Mohan SR, Hsi ED, Theil KS, Maciejewski JP. UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation. Leukemia 2009; 23: 610-614.
112. Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G et al. Characteristics and clinical correlates of MPL 515W4L/K mutation in essential thrombocythemia. Blood 2008; 112: 844-847.
113. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324: 930-935.
114. Lorsbach RB, Moore J, Mathew S, Raimondi SC, Mukatira ST, Downing JR. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 2003; 17: 637-641. (Pubitemid 36395661)
115. Viguie F, Aboura A, Bouscary D, Ramond S, Delmer A, Tachdjian G et al. Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement? Leukemia 2005; 19: 1411-1415. (Pubitemid 41136336)
116. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23: 905-911.
117. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009; 23: 900-904.
118. Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009; 23: 1343-1345.
119. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41: 838-842.
120. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009; 114: 144-147.
121. Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009; 114: 3285-3291.
122. Mohamedali AM, Smith AE, Gaken J, Lea NC, Mian SA, Westwood NB et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol 2009; 27: 4002-4006.
123. Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/ myeloproliferative neoplasms. Blood 2009; 113: 6403-6410.
124. Paulsson K, Haferlach C, Fonatsch C, Hagemeijer A, Andersen MK, Slovak ML et al. The idic(X)(q13) in myeloid malignancies: breakpoint clustering in segmental duplications and association with TET2 mutations. Hum Mol Genet 2010; 19: 1507-1514.
125. Hussein K, Van Dyke DL, Tefferi A. Conventional cytogenetics in myelofibrosis: literature review and discussion. Eur J Haematol 2009; 82: 329-338.
126. Tefferi A, Lim KH, Levine R. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 361: 1117; author reply 1117-1118.
127. Hussein K, Abdel-Wahab O, Lasho TL, Van Dyke DL, Levine RL, Hanson CA et al. Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms. Am J Hematol 2010; 85: 81-83.
128. Kosmider O, Gelsi-Boyer V, Ciudad M, Racoeur C, Jooste V, Vey N et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009; 94: 1676-1681.
129. Couronne L, Lippert E, Andrieux J, Kosmider O, Radford-Weiss I, Penther D et al. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia 2010; 24: 201-203.
130. Lee SW, Cho YS, Na JM, Park UH, Kang M, Kim EJ et al. ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1. J Biol Chem 2010; 285: 18-29.
131. Fisher CL, Pineault N, Brookes C, Helgason CD, Ohta H, Bodner C et al. Loss-of-function additional sex combs-like1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 2010; 115: 38-46.
132. An Q, Wright SL, Konn ZJ, Matheson E, Minto L, Moorman AV et al. Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancer. Proc Natl Acad Sci USA 2008; 105: 17050-17054.
133. Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145: 788-800.
134. Carbuccia N, Trouplin V, Gelsi-Boyer V, Murati A, Rocquain J, Adelaide J et al. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia 2010; 24: 469-473.
135. Swaminathan G, Tsygankov AY. The Cbl family proteins: ring leaders in regulation of cell signaling. J Cell Physiol 2006; 209: 21-43. (Pubitemid 44318665)
136. Saur SJ, Sangkhae V, Geddis AE, Kaushansky K, Hitchcock IS. Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood 2010; 115: 1254-1263.
137. Bandi SR, Brandts C, Rensinghoff M, Grundler R, Tickenbrock L, Kohler G et al. E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. Blood 2009; 114: 4197-4208.
138. Sargin B, Choudhary C, Crosetto N, Schmidt MH, Grundler R, Rensinghoff M et al. Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood 2007; 110: 1004-1012. (Pubitemid 47267440)
139. Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamazaki S et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009; 460: 904-908.
140. Fu JF, Hsu JJ, Tang TC, Shih LY. Identification of CBL, a protooncogene at 11q23.3, as a novel MLL fusion partner in a patient with de novo acute myeloid leukemia. Genes Chromosomes Cancer 2003; 37: 214-219.
141. Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009; 114: 1859-1863.
142. Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 2009; 27: 6109-6116.
143. Muramatsu H, Makishima H, Jankowska AM, Cazzolli H, O'Keefe C, Yoshida N et al. Mutations of E3 ubiquitin ligase Cbl family members but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Blood 2010; 115: 1969-1975.
144. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009; 361: 1872-1885.
145. Flach J, Dicker F, Schnittger S, Kohlmann A, Haferlach T, Haferlach C. Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis (RARS-T). Haematologica 2010; 95: 518-519.
146. Abbas S, Rotmans G, Lowenberg B, Valk PJ. Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias. Haematologica 2008; 93: 1595-1597.
147. Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaus T, Argiropoulos B et al. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res 2009; 15: 2238-2247.
148. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
149. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-1066.
150. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA et al. The common feature of leukemia-associated idh1 and idh2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225-234.
151. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010; 207: 339-344.
152. Gaal J, Burnichon N, Korpershoek E, Roncelin I, Bertherat J, Plouin PF et al. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 2010; 95: 1274-1278.
153. Park SW, Chung NG, Han JY, Eom HS, Lee JY, Yoo NJ et al. Absence of IDH2 codon 172 mutation in common human cancers. Int J Cancer 2009; 125: 2485-2486.
154. Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 2009; 125: 353-355.
155. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 2009; 30: 7-11.
156. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-744.
157. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324: 261-265.
158. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-773.
159. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008; 116: 597-602.
160. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009; 15: 6002-6007.
161. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009; 118: 469-474.
162. Gravendeel LA, Kloosterhof NK, Bralten LB, van Marion R, Dubbink HJ, Dinjens W et al. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum Mutat 2010; 31: E1186-E1199.
163. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009; 27: 4150-4154.
164. Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, Bosch KS et al. The prognostic IDH1 (R132) mutation is associated with reduced NADP (+)-dependent IDH activity in glioblastoma. Acta Neuropathol 2010; 119: 487-494.
165. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27: 5874-5880.
166. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27: 5743-5750.
167. Chou WC, Hou HA, Chen CY, Tang JL, Yao M, Tsay W et al. Distinct clinical and biological characteristics in adult acute myeloid leukemia bearing isocitrate dehydrogenase 1 (IDH1) mutation. Blood 2010, (e-pub ahead of print).
168. Guerini V, Barbui V, Spinelli O, Salvi A, Dellacasa C, Carobbio A et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 2008; 22: 740-747. (Pubitemid 351552623)
169. Mullighan C, Downing J. Ikaros and acute leukemia. Leuk Lymphoma 2008; 49: 847-849. (Pubitemid 351942735)
170. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453: 110-114. (Pubitemid 351630327)
171. Jager R, Gisslinger H, Berg T, Passamonti F, Cazzola M, Rumi E et al. Deletions of the Transcription Factor Ikaros in Myeloproliferative Neoplasms at Transformation to Acute Myeloid Leukemia. ASH Annual Meeting Abstracts 2009; 114: 435.